The FDA has approved Yescarta for use in adult patients with large B-cell lymphoma after at least two other kinds of treatment failed, including DLBCL, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular
Key eligibility criteria include:
All patients who wish to be evaluated for Yescarta must have a referral from their oncologist to DF/BWCC’s Adult Lymphoma Program.
Caron Jacobson, MD, is involved in clinical trials of CAR T-cell therapies for patients with a type of lymphoma.
For more information about lymphoma CAR T-cell therapy, please call 877-801-CART (2278) or email email@example.com.